# First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer

> **NCT03451370** · — · ACTIVE_NOT_RECRUITING · sponsor: **Istituto Oncologico Veneto IRCCS** · enrollment: 121 (estimated)

## Conditions studied

- Elderly Metastatic Colorectal Cancer Patients

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03451370
- **Lead sponsor:** Istituto Oncologico Veneto IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-01
- **Primary completion:** 2027-02
- **Final completion:** 2027-04
- **Target enrollment:** 121 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03451370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03451370, "First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03451370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*